Form 4: Inhibrx Biosciences Director Douglas Forsyth Increases Stake in Company

Director Douglas Forsyth has increased his indirect holdings in Inhibrx Biosciences through purchases made via the Forsyth Family Trust.

Summary

• On August 22, 2024, Douglas Forsyth, a director of Inhibrx Biosciences, indirectly acquired 15,188 shares of common stock through the Forsyth Family Trust at a weighted average price of $12.89 per share.
• Following this transaction, the Forsyth Family Trust held 164,752 shares.
• On August 23, 2024, the Forsyth Family Trust acquired an additional 59,812 shares at a weighted average price of $14.07 per share.
• This increased the Forsyth Family Trust's holdings to 224,564 shares.
• Forsyth is a trustee of the Forsyth Family Trust and may be deemed to indirectly beneficially own the securities held by the trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's purchase indicates confidence, but it's a routine transaction.

Positives

• The director's increased investment could be interpreted as a positive signal about the company's prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders.

Stakeholder Impact

• The increased stake by a director could positively influence shareholder sentiment.

Key Dates